Analyst Price Targets — CASI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2024 7:22 am | Sean Lee | H.C. Wainwright | $6.00 | $3.26 | StreetInsider | CASI Pharmaceuticals (CASI) PT Lowered to $6 at H.C. Wainwright |
| August 15, 2022 10:29 am | — | H.C. Wainwright | $12.00 | $4.02 | Benzinga | HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Adjusts PT to $12 (1-for-10 reverse stock split) |
Latest News for CASI
CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with antibody-mediated rejection (AMR) in organ transplant and various autoimmune diseases, today reported business and financial results for the first half year ended June 30, 2026. "We remained focused…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CASI.
U.S. House Trading
No House trades found for CASI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.